Macaques are the most widely used nonhuman primates in preclinical studies to obtain FDA approval of new drugs but the lack of information on cytochrome P450 genes has hampered the understanding of drug metabolism in this species. Human P450 2C8 metabolizes more than 8% of drugs cleared by Phase I reaction but today there are no data on the substrates recognized by the homologous Macaca fascicularis P450 2C20. In this work, a 3D model of cynomolgus 2C20 was generated and optimized on the basis of the available crystal structure of the P450 2C8 by employing the YASARA program. A set of 60 known substrates of P450 2C8 were taken from the literature and docked in the active site of both the 2C20 model and the available 2C8 structure. Based on the predicted binding energies, both proteins can potentially bind the selected P450 2C8 substrates with similar affinity. In order to validate the in silico docking data by in vitro methods, the gene encoding CYP2C20 was cloned in pCW vector and successfully expressed in E.coli. Furthermore, a chimeric protein consisting of P450 2C20 and the soluble reductase domain of CYP102A1 (Bacillus megaterium-BMR) was engineered. The solubility and catalytic self-sufficiency of this protein would greatly simplify the in vitro preclinical studies of cytochrome P450 2C20 mediated drug metabolism. Three drugs were then selected from the energy output profile of the in silico docking experiments namely Paclitaxel, Torzasertib (anti-cancers) and Amodiaquine (anti-malarial) for in vitro testing with the purified P450 2C20 and its chimera. The turnover of the P450 2C20 and the chimera led to Km values of 1.9±0.2 µM and 5.9±2.3 µM for Paclitaxel; 1.5±0.2 µM and 2.1±0.7 µM for Tozasertib; 1.2±0.2 µM and 1.6 ±0.17 µM for Amodiaquine, respectively. Finally, the data obtained from the in silico and in vitro analysis demonstrate the ability of the cynomolgus P450 2C20 to recognize and turnover P450 2C8 substrates, its human homologue.

From in silico to in vitro substrate characterisation of Macaca fascicularis P450 2C20 / F. Rua; S.J. Sadeghi; G. Gilardi. - In: THE FEBS JOURNAL. - ISSN 1742-464X. - 278(2011), pp. 476-477. ((Intervento presentato al convegno 36th FEBS Congress- Biochemistry for tomorrow's medicine tenutosi a Torino nel 25-30 June 2011.

From in silico to in vitro substrate characterisation of Macaca fascicularis P450 2C20

RUA, FRANCESCO;SADEGHI, JILA;GILARDI, Gianfranco
2011

Abstract

Macaques are the most widely used nonhuman primates in preclinical studies to obtain FDA approval of new drugs but the lack of information on cytochrome P450 genes has hampered the understanding of drug metabolism in this species. Human P450 2C8 metabolizes more than 8% of drugs cleared by Phase I reaction but today there are no data on the substrates recognized by the homologous Macaca fascicularis P450 2C20. In this work, a 3D model of cynomolgus 2C20 was generated and optimized on the basis of the available crystal structure of the P450 2C8 by employing the YASARA program. A set of 60 known substrates of P450 2C8 were taken from the literature and docked in the active site of both the 2C20 model and the available 2C8 structure. Based on the predicted binding energies, both proteins can potentially bind the selected P450 2C8 substrates with similar affinity. In order to validate the in silico docking data by in vitro methods, the gene encoding CYP2C20 was cloned in pCW vector and successfully expressed in E.coli. Furthermore, a chimeric protein consisting of P450 2C20 and the soluble reductase domain of CYP102A1 (Bacillus megaterium-BMR) was engineered. The solubility and catalytic self-sufficiency of this protein would greatly simplify the in vitro preclinical studies of cytochrome P450 2C20 mediated drug metabolism. Three drugs were then selected from the energy output profile of the in silico docking experiments namely Paclitaxel, Torzasertib (anti-cancers) and Amodiaquine (anti-malarial) for in vitro testing with the purified P450 2C20 and its chimera. The turnover of the P450 2C20 and the chimera led to Km values of 1.9±0.2 µM and 5.9±2.3 µM for Paclitaxel; 1.5±0.2 µM and 2.1±0.7 µM for Tozasertib; 1.2±0.2 µM and 1.6 ±0.17 µM for Amodiaquine, respectively. Finally, the data obtained from the in silico and in vitro analysis demonstrate the ability of the cynomolgus P450 2C20 to recognize and turnover P450 2C8 substrates, its human homologue.
36th FEBS Congress- Biochemistry for tomorrow's medicine
Torino
25-30 June 2011
278
476
477
animal cytochrome P450; in silico docking
F. Rua; S.J. Sadeghi; G. Gilardi
File in questo prodotto:
File Dimensione Formato  
Abstract-RUA.pdf

Accesso aperto

Tipo di file: MATERIALE NON BIBLIOGRAFICO
Dimensione 69.52 kB
Formato Adobe PDF
69.52 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/92728
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact